06-22-2018 08:26 AM CET - Advertising, Media Consulting, Marketing Research
Print

Rheumatoid Arthritis – Diseases & Therapeutic Pipeline Review, H1 2018 Covering Key Vendors 3SBio, 4D Pharma PLC, AB Science SA, AbbVie, Ablynx NV

Press release from: HTF Market Intelligence Consulting Pvt. Ltd.
Rheumatoid Arthritis
Rheumatoid Arthritis
HTF Market Report released a new research document of 1016 pages on industry titled as 'Rheumatoid Arthritis - Pipeline Review, H1 2018' with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes important players/vendors such as Adello Biologics LLC, Alteogen , Amarna Therapeutics BV, Amgen, Applied Genetic Technologies etc The report will help you gain market insights, future trends and growth prospects for forecast period.

Request a sample report @ www.htfmarketreport.com/sample-report/1226095-rheumatoid-...
Rheumatoid Arthritis - Pipeline Review, H1 2018

HTF’s latest Pharmaceutical and Healthcare disease pipeline guide Rheumatoid Arthritis - Pipeline Review, H1 2018, provides an overview of the Rheumatoid Arthritis (Immunology) pipeline landscape.
Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.

Report Highlights
HTF’s Pharmaceutical and Healthcare latest pipeline guide Rheumatoid Arthritis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rheumatoid Arthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 13, 1, 28, 47, 63, 1, 6, 207, 49 and 8 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 4, 32 and 5 molecules, respectively.

Rheumatoid Arthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from HTF’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Rheumatoid Arthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rheumatoid Arthritis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rheumatoid Arthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis (Immunology)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rheumatoid Arthritis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rheumatoid Arthritis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Buy this report @ www.htfmarketreport.com/buy-now?format=1&report=1226095

Companies Mentioned in the Report : 3SBio Inc, 4D Pharma PLC, AB Science SA, AbbVie Inc, Ablynx NV, ACEA Biosciences Inc, Aclaris Therapeutics Inc, Adello Biologics LLC, Alteogen Inc, Amarna Therapeutics BV, Amgen Inc, Applied Genetic Technologies Corp, Aptevo Therapeutics Inc, arGentis Pharmaceuticals LLC, Arrien Pharmaceuticals LLC, Arthrogen BV, Asahi Kasei Pharma Corp, Astellas Pharma Inc, AstraZeneca Plc, Atlantic Bio Sci LLC, Aurigene Discovery Technologies Ltd, Axsome Therapeutics Inc, Axxam SpA, Baliopharm AG, Bayer AG, Beijing Hanmi Pharmaceutical Co Ltd, Bio-Cancer Treatment International Ltd, Biocad,Biocon Ltd,Biogen Inc, BioLingus AG, BioLite Inc, Biozeus Pharmaceutical SA,Bird Rock Bio Inc,Boehringer Ingelheim GmbH,Bristol-Myers Squibb Co,BTB Pharma AB,Can-Fite BioPharma Ltd,Cardax Inc,Carna Biosciences Inc,CASI Pharmaceuticals Inc,CEL-SCI Corp,Celgene Corp,Celltrion Inc,Chipscreen Biosciences Ltd,ChironWells GmbH,Chong Kun Dang Pharmaceutical Corp,CJ HealthCare Corp,Clevexel Pharma SAS,Coherus BioSciences Inc,Commence Bio Inc, Compugen Ltd,Crossject SA,CSL Ltd,Cyclacel Pharmaceuticals Inc,Cyxone AB,Daewoong Pharmaceutical Co Ltd,Diamyd Medical AB,Diurnal Group Plc,Domainex Ltd,Dr. Reddy's Laboratories Ltd,Ducentis BioTherapeutics Ltd,Eisai Co Ltd,Enceladus Pharmaceuticals BV,Enzene Biosciences Ltd,F. Hoffmann-La Roche Ltd,Fountain Biopharma Inc,Fresenius SE & Co KGaA,Fujifilm Holdings Corporation,Galapagos NV,Gene Techno Science Co Ltd,Genentech Inc, Genfit SA,Genor BioPharma Co Ltd,Genosco Inc,Gilead Sciences Inc,GlaxoSmithKline Plc,Guangdong Zhongsheng Pharmaceutical Co Ltd,Han Wha Pharma Co Ltd,Hanmi Pharmaceuticals Co Ltd,Hansa Medical AB,Hanwha Chemical Corp,HitGen LTD,Huabo Biopharm Co Ltd,Hualan Biological Engineering Inc,Hutchison MediPharma Ltd,ID Pharma Co Ltd,Idogen AB,Immune Response BioPharma Inc,Immungenetics AG,ImmunoFrontier Inc,ImmunoPrecise Antibodies Ltd,Immunwork Inc,Innate Pharma SA,Innovent Biologics Inc,Intas Pharmaceuticals Ltd,Istesso Ltd,Japan Tobacco Inc,JHL Biotech Inc,Jiangsu Hengrui Medicine Co Ltd,Johnson & Johnson,Jyant Technologies Inc,Kadmon Corp LLC,KAHR medical Ltd,Kang Stem Biotech Co Ltd,KBP BioSciences Co Ltd,Kezar Life Sciences Inc,Lead Pharma Holding BV,LG Chem Ltd,Lipocure Ltd,Livzon Pharmaceutical Group Inc,LSK BioPartners Inc,Lupin Ltd,Mabion SA,mAbxience SA,Maruho Co Ltd,Mebiopharm Co Ltd,MedAnnex Ltd,MedImmune LLC,Merck & Co Inc, Merck KGaA,Mesoblast Ltd,Millennium Pharmaceuticals Inc,Mitsubishi Tanabe Pharma Corp,Momenta Pharmaceuticals Inc,Morphotek Inc,Mycenax Biotech Inc,MYOS RENS Technology Inc,Navigen Inc,Nichi-Iko Pharmaceutical Co Ltd,Nissan Chemical Industries Ltd,Nordic Group BV,Novartis AG,NovelMed Therapeutics Inc,NovImmune SA,Nuevolution AB,Numab Innovation AG,Omeros Corp,Oncodesign SA,OncoImmune Inc,Ono Pharmaceutical Co Ltd,OSE Immunotherapeutics,Paras Biopharmaceuticals Finland Oy,Peptinov SAS,Pfizer Inc,Pharmedartis GmbH,Philogen SpA,PlantForm Corp,PLx Pharma Inc,Principia Biopharma Inc,ProNoxis AB,Protab Ltd,Protalex Inc,Protheragen Inc,Qilu Pharmaceutical Co Ltd,Qu Biologics Inc,R Pharm,ReceptoPharm Inc,RedHill Biopharma Ltd,Reliance Life Sciences Pvt Ltd,Resverlogix Corp,ReveraGen BioPharma Inc,Rhizen Pharmaceuticals SA,Ribomic Inc,Richter Gedeon Nyrt,Rottapharm Biotech Srl,Saje Pharma LLC,Sandoz International GmbH,Sareum Holdings Plc,SBI Biotech Co Ltd,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd,Shanghai Henlius Biotech Co Ltd,Shanghai Pharmaceutical Co Ltd,Simcere Pharmaceutical Group,Synermore Biologics Co Ltd,Taiho Pharmaceutical Co Ltd,Takeda Pharmaceutical Co Ltd,Teijin Pharma Ltd,TheraMAB LLC,Tiziana Life Sciences Plc,Toleranzia AB,TTY Biopharm Company Ltd,Tumorend LLC,Twoxar Inc,TxCell SA,UCB SA,United BioPharma Inc,Vaccinex Inc,Valeant Pharmaceuticals International Inc,Vicore Pharma AB,X-Rx Inc,Xbrane Biopharma AB,XL-protein GmbH,YiChang Humanwell Pharmaceutical Co Ltd,Yungjin Pharm Co Ltd,Yuyu Pharma Inc,Zhejiang Hisun Pharmaceutical Co Ltd

Get Customization in the Report, Enquire Now @ www.htfmarketreport.com/enquiry-before-buy/1226095-rheuma...

Introduction 10
Rheumatoid Arthritis - Overview 11
Rheumatoid Arthritis - Therapeutics Development 12
Rheumatoid Arthritis - Therapeutics Assessment 60
Rheumatoid Arthritis - Companies Involved in Therapeutics Development 80
Rheumatoid Arthritis - Drug Profiles 167
Rheumatoid Arthritis - Dormant Projects 915
Rheumatoid Arthritis - Discontinued Products 950
Rheumatoid Arthritis - Product Development Milestones 957
Appendix 971List of Tables
Number of Products under Development for Rheumatoid Arthritis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..11), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..12), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..13), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Products under Development by Companies, H1 2018 (Contd..8), H1 2018
Products under Development by Companies, H1 2018 (Contd..9), H1 2018
Products under Development by Companies, H1 2018 (Contd..10), H1 2018
Products under Development by Companies, H1 2018 (Contd..11), H1 2018
Products under Development by Companies, H1 2018 (Contd..12), H1 2018
Products under Development by Companies, H1 2018 (Contd..13), H1 2018
Products under Development by Companies, H1 2018 (Contd..14), H1 2018
Products under Development by Companies, H1 2018 (Contd..15), H1 2018
Products under Development by Companies, H1 2018 (Contd..16), H1 2018
Products under Development by Companies, H1 2018 (Contd..17), H1 2018
Products under Development by Companies, H1 2018 (Contd..18), H1 2018
Products under Development by Companies, H1 2018 (Contd..19), H1 2018
Products under Development by Companies, H1 2018 (Contd..20), H1 2018
Products under Development by Companies, H1 2018 (Contd..21), H1 2018
Products under Development by Companies, H1 2018 (Contd..22), H1 2018
Products under Development by Companies, H1 2018 (Contd..23), H1 2018
Products under Development by Universities/Institutes, H1 2018
Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..6), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage

....Continued

View Detailed Table of Content @ www.htfmarketreport.com/reports/1226095-rheumatoid-arthri...

It's vital you keep your market knowledge up to date. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization accordingly.

HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com

Connect with us at
www.linkedin.com/company/13388569/
plus.google.com/u/0/+NidhiBhawsar-SEO_Expert?rel=author
www.facebook.com/htfmarketintelligence/
twitter.com/htfmarketreport

This release was published on openPR.
News-ID: 1093224 • Views: 698
More releasesMore releases

You can edit or delete your press release here: